Anders W. Jørgensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anders W. Jørgensen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Annesofie Faurschou
Department of Dermatology, University of Copenhagen, Bispebjerg Hospital, Copenhagen, Denmark
1 shared publication - Britta Tendal
Nordic Cochrane Centre, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark
1 shared publication Karsten Juhl Jørgensen
The Nordic Cochrane Centre, Copenhagen, Denmark
1 shared publication- Katja L Maric
The Nordic Cochrane Centre, Department 3343, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
1 shared publication Peter C. Gøtzsche
The Nordic Cochrane Centre, Copenhagen, Denmark
1 shared publication- Peter Christian Gøtzsche
Institute for Scientific Freedom
1 shared publication
Latest Publications
- 17 February 2010
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 66 (4) , 341-347
Unbalanced reporting of benefits and harms in abstracts on rofecoxib
Purpose It was predicted from the mechanism of action that, compared to older non-steroidal anti-inflammatory drugs, rofecoxib (Vioxx) would reduce gastrointestinal bleeding, but also that it would increase the occurrence of cardiovascular thrombosis. From the patient’s point of view, both effects are important and should be investigated and reported similarly. We studied how they have been reported over time. Methods We searched PubMed for abstracts on rofecoxib that commented on gastrointestinal bleeding or cardiovascular thrombosis or both. Two researchers, blinded to date of publication and authors, assessed the abstracts independently. We judged the authors' view on rofecoxib and comments on gastrointestinal bleeding and thrombosis as being favourable, neutral or unfavourable towards rofecoxib. Results We included 393 abstracts commenting on gastrointestinal bleeding (72%) and cardiovascular thrombosis (54%) or both. Before October 2000, all abstracts (n = 27) mentioned only gastrointestinal bleeding and 89% were positive towards rofecoxib. The year before the withdrawal of rofecoxib (October 2003 to September 2004) (n = 46), 59% of abstracts commented on gastrointestinal bleeding only, 17% on thrombosis only, 24% on both and 67% were still positive. From October 2006 to September 2007 (n = 54), 13% mentioned gastrointestinal bleeding, 54% thrombosis, 33% mentioned both and only 11% were positive. Conclusions The reporting of benefits and harms was not balanced and changed markedly over time. Knowledge of increased risk of thrombosis existed early on, but the harms came into focus too late, when the drug was already withdrawn, and when tens of thousands of patients had been harmed unnecessarily.
- 17 February 2010
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 66 (4) , 341-347
Unbalanced reporting of benefits and harms in abstracts on rofecoxib
Purpose It was predicted from the mechanism of action that, compared to older non-steroidal anti-inflammatory drugs, rofecoxib (Vioxx) would reduce gastrointestinal bleeding, but also that it would increase the occurrence of cardiovascular thrombosis. From the patient’s point of view, both effects are important and should be investigated and reported similarly. We studied how they have been reported over time. Methods We searched PubMed for abstracts on rofecoxib that commented on gastrointestinal bleeding or cardiovascular thrombosis or both. Two researchers, blinded to date of publication and authors, assessed the abstracts independently. We judged the authors' view on rofecoxib and comments on gastrointestinal bleeding and thrombosis as being favourable, neutral or unfavourable towards rofecoxib. Results We included 393 abstracts commenting on gastrointestinal bleeding (72%) and cardiovascular thrombosis (54%) or both. Before October 2000, all abstracts (n = 27) mentioned only gastrointestinal bleeding and 89% were positive towards rofecoxib. The year before the withdrawal of rofecoxib (October 2003 to September 2004) (n = 46), 59% of abstracts commented on gastrointestinal bleeding only, 17% on thrombosis only, 24% on both and 67% were still positive. From October 2006 to September 2007 (n = 54), 13% mentioned gastrointestinal bleeding, 54% thrombosis, 33% mentioned both and only 11% were positive. Conclusions The reporting of benefits and harms was not balanced and changed markedly over time. Knowledge of increased risk of thrombosis existed early on, but the harms came into focus too late, when the drug was already withdrawn, and when tens of thousands of patients had been harmed unnecessarily.
- Open Access
- 9 September 2008
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 8 (1) , 60
Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions
Studies have shown that industry-sponsored meta-analyses of drugs lack scientific rigour and have biased conclusions. However, these studies have been restricted to certain medical specialities. We compared all industry-supported meta-analyses of drug-drug comparisons with those without industry support.
- 9 September 2008
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 8 (1) , 60
Open AccessIndustry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions
Studies have shown that industry-sponsored meta-analyses of drugs lack scientific rigour and have biased conclusions. However, these studies have been restricted to certain medical specialities. We compared all industry-supported meta-analyses of drug-drug comparisons with those without industry support.